IMAC Holdings, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Faith Zaslavsky
- Full Time Employees
- 15
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 3401 Mallory Lane Franklin TN United States of America 37027
- IPO Date
- Feb 13, 2019
- CIK
- 0001729944
- Website
- imacregeneration.gcs-web.com
- Similar Companies
- Business
- IMAC Holdings, Inc. (NASDAQ: BACK) provides proteomic products and precision medicine services based on activated protein analysis for cancer treatment through its subsidiary Ignite Proteomics LLC; the company offers a reverse phase protein array (RPPA) platform that quantifies protein signaling to support oncology clinical treatment decisions, particularly for advanced breast cancer patients, and biopharmaceutical drug development; its lab-developed tests (LDTs) assist oncologists in creating targeted treatment plans across the United States. Founded in 2000 and headquartered in Franklin, Tennessee, IMAC operates in the biotechnology sector focusing on oncology, with recent strategic shifts from prior orthopedic and regenerative therapies to precision medicine. In May 2024, IMAC acquired key assets from Theralink Technologies to advance its precision medicine business in breast cancer diagnostics, resolving prior debt issues and terminating a planned merger; the company appointed Jeffrey M. Busch as board chairman, along with oncology experts Dr. Peter Beitsch and Dr. Matthew M. Schwartz as independent directors in 2024; in November 2024, it secured $3.74 million through a PIPE financing via Series G convertible preferred stock and warrants, plus a $60 million equity line agreement subject to SEC approval; IMAC also regained Nasdaq compliance with minimum stockholders' equity via the Theralink asset deal and amended its 2018 Incentive Compensation Plan to increase authorized shares.
Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers
Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference
Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay
Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response
IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies
IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
IMAC Holdings Granted Extension by Nasdaq to Regain Compliance with Listing Rule 5250(c)(1)
IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology
IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors
IMAC Holdings Announces Leadership Succession
IMAC Holdings Acquires Assets of Theralink to Continue Precision Medicine Business
IMAC Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements
IMAC Holdings, Inc. Announces 1-for-30 Reverse Stock Split
If You Can Only Buy One Penny Stock, It Better Be One of These 3 Names
IMAC Holdings Announces $4.3 Million Private Placement of Convertible Preferred Stock and Warrants Priced at the Market
Imac Holdings (IMAC) Receives a New Rating from Ascendiant